Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic and extra-pancreatic neuroendocrine tumors.
Approval Alert | Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Plus Lenvatinib Improves PFS/ORR in Advanced Pretreated RCC
2
JSKN003 Receives FDA Fast Track Designation in Advanced PROC
3
Response Rates Show Promise in Phase 1 trial Involving ASCT in Metastatic PDAC
4
Case 2: Patient With High-Risk RRMM Relapsing After BCMA CAR T-Cell Therapy
5
